- Home
- VTLE vs TVTX Comparison
VTLE vs TVTX Comparison
Compare VTLE & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- TVTX
- Stock Information
- Founded
- VTLE 2006
- TVTX 2008
- Country
- VTLE United States
- TVTX United States
- Employees
- VTLE N/A
- TVTX N/A
- Industry
- VTLE
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- TVTX Health Care
- Exchange
- VTLE Nasdaq
- TVTX Nasdaq
- Market Cap
- VTLE 1.2B
- TVTX 1.3B
- IPO Year
- VTLE 2011
- TVTX N/A
- Fundamental
- Price
- VTLE $30.66
- TVTX $17.72
- Analyst Decision
- VTLE Hold
- TVTX Buy
- Analyst Count
- VTLE 13
- TVTX 13
- Target Price
- VTLE $47.91
- TVTX $23.46
- AVG Volume (30 Days)
- VTLE 849.1K
- TVTX 1.4M
- Earning Date
- VTLE 11-06-2024
- TVTX 10-31-2024
- Dividend Yield
- VTLE N/A
- TVTX N/A
- EPS Growth
- VTLE N/A
- TVTX N/A
- EPS
- VTLE 13.16
- TVTX N/A
- Revenue
- VTLE $1,862,465,000.00
- TVTX $203,447,000.00
- Revenue This Year
- VTLE $28.07
- TVTX $62.45
- Revenue Next Year
- VTLE $7.97
- TVTX $59.30
- P/E Ratio
- VTLE $2.35
- TVTX N/A
- Revenue Growth
- VTLE 26.94
- TVTX 57.08
- 52 Week Low
- VTLE $25.85
- TVTX $5.12
- 52 Week High
- VTLE $58.30
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- VTLE 62.67
- TVTX 51.53
- Support Level
- VTLE $29.51
- TVTX $16.89
- Resistance Level
- VTLE $32.24
- TVTX $19.51
- Average True Range (ATR)
- VTLE 1.38
- TVTX 1.23
- MACD
- VTLE 0.50
- TVTX -0.16
- Stochastic Oscillator
- VTLE 86.72
- TVTX 26.69
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.